Business Context and Reporting Period
This Form 8-K, dated April 15, 2025, reports the completion of a merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc. Effective April 15, 2025, Cara changed its name to Tvardi Therapeutics, Inc. (the "Company"). The Company is a clinical-stage biopharmaceutical firm focused on developing oral small molecule STAT3 inhibitors for fibrosis-driven diseases. The filing also details a concurrent 1-for-3 reverse stock split and the divestiture of Cara's difelikefalin assets.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, or cash flow figures for the combined entity in this text, as the Company is a clinical-stage biopharmaceutical company with no commercial product sales. Financial statements are incorporated by reference from other filings.
- Share Capital: Following the merger and reverse stock split, there are 9,355,542 shares of common stock issued and outstanding.
- Stock Conversion: Tvardi stockholders received 7,805,161 shares based on an exchange ratio of 0.1341. Convertible notes with a principal of approximately $28.3 million and $0.8 million in accrued interest were converted into 9,355,542 shares (Note: The text states the total post-merger shares are 9,355,542, implying the conversion of notes and Tvardi shares resulted in this total count, with pre-Merger Cara holders retaining ~15.4%).
- Asset Disposition: The Company sold difelikefalin assets to CSL Vifor for $900,000 (subject to adjustments) and paid CSL Vifor $3,000,000 to cover incremental future expenses related to the transfer.
- Intellectual Property Obligations: The Company holds exclusive licenses from Baylor College of Medicine (BCM) with potential milestone payments up to $2,200,000 (BCM First Agreement) and $1,225,000 (BCM Second Agreement), plus low-single-digit royalties on net sales.
Material Changes Versus Prior Period
- Corporate Identity: The registrant changed its name from "Cara Therapeutics, Inc." to "Tvardi Therapeutics, Inc." and its ticker symbol from "CARA" to "TVRD" (effective April 16, 2025).
- Capital Structure: A 1-for-3 reverse stock split was executed. Authorized shares were increased to 150,000,000.
- Ownership Composition: Post-merger ownership is approximately 72.0% held by pre-Merger Tvardi equityholders, 15.4% by pre-Merger Cara equityholders, and 12.5% by former holders of Tvardi Convertible Notes.
- Asset Portfolio: The Company divested its difelikefalin asset (including related licenses and supply agreements) to CSL Vifor, shifting its focus entirely to its STAT3 inhibitor pipeline (TTI-101 and TTI-109).
- Leadership: The board of directors was reconstituted with six members designated by Tvardi and one by Cara. Former Cara executives (CEO, CFO, General Counsel) were terminated with severance packages.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- TTI-101 (Lead Candidate): In Phase 2 for Idiopathic Pulmonary Fibrosis (IPF) and Phase 1b/2 for Hepatocellular Carcinoma (HCC). Unblinded IPF data is expected in the second half of 2025; preliminary HCC data is expected in the first half of 2026.
- TTI-109: A prodrug of TTI-101 designed to improve tolerability. An Investigational New Drug (IND) application is expected in the first half of 2025.
- Commercial Strategy: The Company does not anticipate needing commercial licenses for standard of care therapies if its products are approved.
- Legal Proceedings: Two lawsuits were filed in March 2025 by purported stockholders challenging the merger disclosures. The Company intends to vigorously defend these claims but voluntarily supplemented disclosures to moot the claims.
- Financial Runway: As a clinical-stage company, the Company relies on capital raises to fund operations. The filing notes risks regarding the ability to raise capital.
- Development Risks: Forward-looking statements regarding clinical trial results, regulatory approvals, and commercial potential are subject to significant uncertainty.
Investor Verification Checklist
- Pro Forma Financials: Review Exhibit 99.5 for unaudited pro forma condensed combined financial information as of December 31, 2024, to assess the combined entity's liquidity and debt position.
- Cash Runway: Verify the Company's current cash balance and projected burn rate given the cessation of difelikefalin revenue streams and the ongoing costs of Phase 2 clinical trials.
- Legal Status: Monitor the status of the stockholder lawsuits (Clark and Kent Complaints) filed in March 2025 regarding merger disclosures.
- Intellectual Property: Confirm the specific terms of the BCM license agreements (Exhibits 10.3 and 10.4) regarding milestone payment triggers and royalty rates.
- Stock Liquidity: Verify trading volume and price stability under the new ticker "TVRD" following the 1-for-3 reverse stock split.